Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Psychiatry Reports
Published in: Current Psychiatry Reports 1/2015

01-01-2015 | Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

Psychopharmacology in Cancer

Authors: Seema M. Thekdi, Antolin Trinidad, Andrew Roth

Published in: Current Psychiatry Reports | Issue 1/2015

Login to get access

Abstract

Depression, anxiety, delirium, and other psychiatric symptoms are highly prevalent in the cancer setting, and pharmacological intervention is an important component in the overall psychosocial care of the patient. Psychopharmacology is also used as a primary or adjuvant treatment for the management of cancer-related symptoms stemming from the disease itself and/or its treatment, including sleep disturbance, loss of appetite, neuropathic pain, nausea, fatigue, and hot flashes. Psychiatrists, oncologists, and palliative care physicians working as members of a multidisciplinary team have the opportunity to target multiple symptoms that negatively affect a patient’s quality of life with the strategic use of psychotropic medications when deemed appropriate. This article aims to review the indications for use of antidepressants, psychostimulants, anxiolytics, antipsychotics, and mood stabilizers in oncology. An updated review of the relevant literature is discussed and referenced in each section.
Literature
1.
Mitchell AJ et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol. 2011;12(2):160–74.PubMedCrossRef
2.
Pirl WF, Roth AJ. Diagnosis and treatment of depression in cancer patients. Oncology (Williston Park). 1999;13(9):p. 1293–301. Discussion 1301–2, 1305–6.
3.
Holland JC et al. Distress management. J Natl Compr Canc Netw. 2013;11(2):190–209.PubMed
4.
American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders DSM-5, 5th edn. American Psychiatric Association, Washington, DC
5.
Lee BN et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation. 2004;11(5):279–92.PubMedCrossRef
6.
Thekdi SM IM, Dunn L. Psychopharmacological interventions. In: Grassi RM, editor. Clinical psych-oncology: an international perspective. Chichester: Wiley-Blackwell; 2012. p. 109–26.CrossRef
7.
Desplenter F et al. Incidence and drug treatment of emotional distress after cancer diagnosis: a matched primary care case-control study. Br J Cancer. 2012;107(9):1644–51.PubMedCentralPubMedCrossRef
8.
Ng CG et al. Prescription patterns for psychotropic drugs in cancer patients; a large population study in the Netherlands. Psychooncology. 2013;22(4):762–7.PubMedCrossRef
9.
10.•
Grassi L et al. Efficacy and safety of pharmacotherapy in cancer-related psychiatric disorders across the trajectory of cancer care: a review. Int Rev Psychiatry. 2014;26(1):44–62. This review article includes a search of the major databases (MEDLINE, Embase, PsycLIT, PsycINFO, the Cochrane Library) and summarizes relevant data concerning the efficacy and safety of pharmacotherapy for cancer-related psychiatric disorders in cancer patients across the trajectory of the disease.PubMedCrossRef
11.
McDaniel JS et al. Depression in patients with cancer. Diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995;52:89–99.PubMedCrossRef
12.
Sharpe M et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer. 2004;90(2):314–20.PubMedCentralPubMedCrossRef
13.
Strouse TB. Psychopharmacologic treatment of depression in patients with cancer: a 2013 update. FOCUS 2013. 2013;11:450–9.
14.
Stockler MR, O’Connell R, Nowak AK, et al. Effects of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trial. Lancet Oncol. 2007;8:603–12.PubMedCrossRef
15.
Miller AH. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2008;65(9):p. 732–741.CrossRef
16.
Danzer R, O’Connor J, Freund GG. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56.CrossRef
17.
Tynan RJ et al. A comparative examination of the anti-inflammatory effects of SSRI and SNRI antidepressants on LPS stimulated microglia. Brain Behav Immun. 2012;26(3):469–79.PubMedCrossRef
18.
Mun AR et al. Fluoxetine-induced apoptosis in hepatocellular carcinoma cells. Anticancer Res. 2013;33(9):3691–7.PubMed
19.
De Fazio P et al. Mental adjustment to cancer: the role of anxious and depressive symptoms under treatment. Int J Psychiatry Med. 2013;46(4):375–86.PubMedCrossRef
20.
Strong V et al. Management of depression for people with cancer 4 (SMaRT oncology 1): a randomised trial. Lancet. 2008;372(9632):40–8.PubMedCrossRef
21.
Holland JC et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology. 1998;7(4):291–300.PubMedCrossRef
22.
Fisch MJ et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol. 2003;21(10):1937–43.PubMedCrossRef
23.
Schillani G et al. Pharmacogenetics of escitalopram and mental adaptation to cancer in palliative care: report of 18 cases. Tumori. 2011;97(3):358–61.PubMed
24.•
Lydiatt WM et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer randomized, double-blind, placebo-controlled clinical trial. JAMA Otolaryngol-Head Neck Surg. 2013;139(7):p. 678–686. This is an interesting study suggesting that certain depressive states can be prevented, in turn abutting the issue of whether certain depressive states in cancer may be explained by biochemically identifiable mechanisms such as inflammation.
25.•
Callari A et al. Treatment of depression in patients with breast cancer: a critical review. Tumori. 2013;99(5):p. 623–633. This article reviews the relevant evidence for the efficacy of SSRIs in breast cancer. The importance of the study is that it separates certain forms of pharmacologically treatable depression from general distress in cancer patients.
26.
Kim SW et al. Effectiveness of mirtazapine for nausea and insomnia in cancer patients with depression. Psychiatry Clin Neurosci. 2008;62(1):75–83.PubMedCrossRef
27.
Moss EL et al. An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology. 2006;15(3):259–67.PubMedCrossRef
28.
Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.PubMed
29.
Smith EM et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309(13):1359–67.PubMedCentralPubMedCrossRef
30.
Amr YM, Yousef AA. Evaluation of efficacy of the perioperative administration of venlafaxine or gabapentin on acute and chronic postmastectomy pain. Clin J Pain. 2010;26(5):381–5.PubMedCrossRef
31.
Durand JP et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2012;23(1):200–5.PubMedCrossRef
32.
L’Esperance S et al. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer. 2013;21(5):1461–74.PubMedCrossRef
33.
Miguel C, Albuquerque E. Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology. 2011;88(5–6):333–9.PubMedCrossRef
34.
Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6. J Clin Psychiatry. 2009;70(12):1688–97.PubMedCrossRef
35.
Kelly CM et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Br Med J. 2010;340.
36.
Regan MM et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst. 2012;104(6):441–51.PubMedCentralPubMedCrossRef
37.
38.
Zembutsu H et al. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011;11(2):185–93.PubMedCrossRef
39.
Ahmad A, Shahabuddin S, Sheikh S. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin Pharmacol Ther. 2010;88(6):814–7.PubMedCrossRef
40.
Portenoy RK et al. The memorial symptom assessment scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30A(9):1326–36.PubMedCrossRef
41.
Macleod AD. Methylphenidate in terminal depression. J Pain Symptom Manag. 1998;16(3):193–8.CrossRef
42.
Olin J, Masand P. Psychostimulants for depression in hospitalized cancer patients. Psychosomatics. 1996;37(1):57–62.PubMedCrossRef
43.
Bruera E et al. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain. 1992;50(1):75–7.PubMedCrossRef
44.
Gagnon B, Low G, Schreier G. Methylphenidate hydrochloride improves cognitive function in patients with advanced cancer and hypoactive delirium: a prospective clinical study. J Psychiatry Neurosci. 2005;30(2):100–7.PubMedCentralPubMed
45.
Prommer E. Methylphenidate: established and expanding roles in symptom management. Am J Hosp Palliat Care. 2012;29(6):483–90.PubMedCrossRef
46.
Minton O et al. Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev. 2010;7, CD006704.PubMed
47.
48.
Bruera E et al. Methylphenidate and/or a nursing telephone intervention for fatigue in patients with advanced cancer: a randomized, placebo-controlled, phase II trial. J Clin Oncol. 2013;31(19):2421–7.PubMedCentralPubMedCrossRef
49.
Moraska AR et al. Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol. 2010;28(23):3673–9.PubMedCentralPubMedCrossRef
50.
Jean-Pierre P et al. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010;116(14):3513–20.PubMedCentralPubMedCrossRef
51.
Spathis A et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. J Clin Oncol. 2014;32(18):1882–8.PubMedCrossRef
52.
53.
54.
Boettger S, Breitbart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care. 2011;9(4):351–7.PubMedCrossRef
55.
Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clin. 2008;24(4):657–722. vii.PubMedCrossRef
56.•
Wang HR, Woo YS, Bahk WM. Atypical antipsychotics in the treatment of delirium. Psychiatry Clin Neurosci. 2013;67(5):p. 323–31. This paper reviews six prospective, randomized controlled studies evaluating the efficacy, safety, and tolerability of atypical antipsychotics in the treatment of delirium.CrossRef
57.
Yoon HK et al. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial. Acta Neuropsychiatrica. 2011;23(4):179–83.PubMedCrossRef
58.
Anderson R et al. Lurasidone for the management of intensive care unit (ICU)-associated delirium. Crit Care Med. 2012;40(12):1–328.
59.•
Teslyar P et al. Prophylaxis with antipsychotic medication reduces the risk of post-operative delirium in elderly patients: a meta-analysis. Psychosomatics. 2013;54(2):p. 124–31. This paper reviews five studies examining the use of antipsychotics (haloperidol, risperidone, and olanzapine) in the prevention of postoperative delirium in elderly patients. Pooled analysis revealed a relative risk reduction of 50 % versus placebo.CrossRef
60.
Pasquini M, Speca A, Biondi M. Quetiapine for tamoxifen-induced insomnia in women with breast cancer. Psychosomatics. 2009;50(2):159–61.PubMedCrossRef
61.
62.
Han C et al. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence. Expert Rev Neurother. 2013;13(7):851–70.PubMedCrossRef
63.
Lorenz RA, Jackson CW, Saitz M. Adjunctive use of atypical antipsychotics for treatment-resistant generalized anxiety disorder. Pharmacotherapy. 2010;30(9):942–51.PubMedCrossRef
64.
McLean SL, Blenkinsopp A, Bennett MI. Using haloperidol as an antiemetic in palliative care: informing practice through evidence from cancer treatment and postoperative contexts. J Pain Palliat Care Pharmacother. 2013;27(2):132–5.PubMedCrossRef
65.
Smith HH. Palliative Medicine. Philadelphia: Saunders Elsevier; 2009. p. 894–8.CrossRef
66.
Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22(4):1143–51.PubMedCrossRef
67.
Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8):951–6.PubMedCrossRef
68.•
Rahman T et al. Antipsychotic treatment in breast cancer patients. Am J Psychiatry. 2014;171(6):p. 616–21. This paper reviews the issue of prescribing antipsychotics in the context of breast cancer, a concern often raised by patients to their clinicians requiring the most up-to-date information.CrossRef
69.
Leucht S et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.PubMedCrossRef
70.
Linden W et al. Anxiety and depression after cancer diagnosis: prevalence rates by cancer type, gender, and age. J Affect Disord. 2012;141(2–3):343–51.PubMedCrossRef
71.
Noyes R, Holt C, Massie M. Anxiety disorders. In: Holland J, editor. Psycho-oncology. New York: Oxford University Press; 1998. p. 548–63.
72.
73.
Prieto JM et al. Psychiatric morbidity and impact on hospital length of stay among hematologic cancer patients receiving stem-cell transplantation. J Clin Oncol. 2002;20(7):1907–17.PubMedCrossRef
74.
Lavigne JE et al. A randomized, controlled, double-blinded clinical trial of gabapentin 300 versus 900 mg versus placebo for anxiety symptoms in breast cancer survivors. Breast Cancer Res Treat. 2012;136(2):479–86.PubMedCrossRef
75.•
Lindgren ME et al. Beta-blockers may reduce intrusive thoughts in newly diagnosed cancer patients. Psychooncology. 2013;22(8):p. 1889–94. The results of this study suggest that beta-blocker use may benefit cancer patients’ psychological adjustment following diagnosis, and provide a promising direction for future investigations on the pharmacological benefits of beta-blockers for cancer-related distress.CrossRef
76.
Dundar Y et al. Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis. Hum Psychopharmacol. 2004;19(5):305–22.PubMedCrossRef
77.
Terzano MG et al. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf. 2003;26(4):261–82.PubMedCrossRef
78.
79.
Costantini C, Ale-Ali A, Helsten T. Sleep aid prescribing practices during neoadjuvant or adjuvant chemotherapy for breast cancer. J Palliat Med. 2011;14(5):563–6.PubMedCrossRef
80.
Joffe H et al. Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes: a randomized, double-blind, placebo-controlled trial. Menopause. 2010;17(5):908–16.PubMedCrossRef
81.
Candy B et al. Drug therapy for symptoms associated with anxiety in adult palliative care patients. Cochrane Database Syst Rev. 2012;10:Cd004596.PubMed
82.
Testa A et al. Psychiatric emergencies (part II): psychiatric disorders coexisting with organic diseases. Eur Rev Med Pharmacol Sci. 2013;17 Suppl 1:65–85.PubMed
83.•
Vaidya R et al. Benzodiazepine use in breast cancer survivors: findings from a consecutive series of 1,000 patients. Oncology. 2011;81(1):p. 9–11. This study reports the percentage of breast cancer survivors (almost 8 %) receiving ongoing benzodiazepines and the circumstances surrounding their usage following 1000 consecutive women with breast cancers.CrossRef
84.
Altamura AC et al. Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Rev Neurother. 2011;11(1):85–99.PubMedCrossRef
85.
Kargiotis O, Markoula S, Kyritsis AP. Epilepsy in the cancer patient. Cancer Chemother Pharmacol. 2011;67(3):489–501.PubMedCrossRef
86.
Eisenberg E et al. Antiepileptic drugs in the treatment of neuropathic pain. Drugs. 2007;67(9):1265–89.PubMedCrossRef
87.
Petrini M, Azzara A. Lithium in the treatment of neutropenia. Curr Opin Hematol. 2012;19(1):52–7.PubMedCrossRef
88.
89.
Bowden CL. Spectrum of effectiveness of valproate in neuropsychiatry. Expert Rev Neurother. 2007;7(1):9–16.PubMedCrossRef
90.
Andersohn F et al. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology. 2010;75(4):335–40.PubMedCrossRef
91.
Guthrie GD, Eljamel S. Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme. J Neurosurg. 2013;118(4):859–65.PubMedCrossRef
92.
Yap KY, Chui WK, Chan A. Drug interactions between chemotherapeutic regimens and antiepileptics. Clin Ther. 2008;30(8):1385–407.PubMedCrossRef
93.
Loprinzi CL, Barton DL, Qin R. Nonestrogenic management of hot flashes. J Clin Oncol. 2011;29(29):3842–6.PubMedCrossRef
94.
Loprinzi CL et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol. 2010;28(4):641–7.PubMedCentralPubMedCrossRef
95.
Bar Ad V. Gabapentin for the treatment of cancer-related pain syndromes. Rev Recent Clin Trials. 2010;5(3):174–8.PubMedCrossRef
96.
Bennett MI et al. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013;14(11):1681–8.PubMedCrossRef
97.
98.
Ryan NM, Birring SS, Gibson PG. Gabapentin for refractory chronic cough: a randomised, double-blind, placebo-controlled trial. Lancet. 2012;380(9853):1583–9.PubMedCrossRef
99.
Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012;46(3):424–9.PubMedCrossRef
100.
Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2013;12, CD006044.PubMed
101.
Bendaly EA et al. Topiramate in the treatment of neuropathic pain in patients with cancer. Support Cancer Ther. 2007;4(4):241–6.PubMedCrossRef
102.
Reas DL, Grilo CM. Current and emerging drug treatments for binge eating disorder. Expert Opin Emerg Drugs. 2014;19:99–142.PubMedCrossRef
103.
Argyriou AA et al. Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology. 2006;67(12):2253–5.PubMedCrossRef
Metadata
Title
Psychopharmacology in Cancer
Authors
Seema M. Thekdi
Antolin Trinidad
Andrew Roth
Publication date
01-01-2015
Publisher
Springer US
Published in
Current Psychiatry Reports / Issue 1/2015
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI
https://doi.org/10.1007/s11920-014-0529-x

Other articles of this Issue 1/2015

Current Psychiatry Reports 1/2015 Go to the issue

Anxiety Disorders (A Pelissolo, Section Editor)

Internet-Delivered Cognitive Behavior Therapy for Anxiety Disorders Is Here to Stay

Personality Disorders (C Schmahl, Section Editor)

Personality Disorders in Older Adults: Emerging Research Issues

Personality Disorders (C Schmahl, Section Editor)

Pharmacotherapy for Borderline Personality Disorder—Current Evidence and Recent Trends

Complex Medical-Psychiatric Issues (MB Riba, Section Editor)

The Bidirectional Relation Between Psychiatric Disorders With Selected Cardiovascular and Endocrinal Diseases: An Egyptian Perspective

Anxiety Disorders (A Pelissolo, Section Editor)

d-Cycloserine Augmentation of Cognitive Behavioral Therapy for Anxiety Disorders: an Update

Psychiatric Diagnosis (MB First, Section Editor)

Melancholia and Catatonia: Disorders or Specifiers?